Brookings Report Examines Revenue Streams, Profitability Of HIV Treatments

Brookings Institution’s “TechTank”: How profitable are HIV drugs?
Jake Schneider, research assistant, and Darrell West, vice president and director of governance studies and founding director of the Center for Technology Innovation, both at the Brookings Institution, discuss findings from their newly released report examining the estimated potential returns to private investors in antiretroviral therapies and the profitability of HIV drugs in various countries and regions. The authors offer several recommendations for how to overcome barriers to investment in emerging markets (4/16).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.